Phathom Pharmaceuticals
PHAT
144 hedge funds and large institutions have $541M invested in Phathom Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 60 increasing their positions, 26 reducing their positions, and 22 closing their positions.
131% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 26
64% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 22
8% more funds holding
Funds holding: 133 → 144 (+11)
8.85% less ownership
Funds ownership: 106.36% → 97.51% (-8.9%)
42% less funds holding in top 10
Funds holding in top 10: 12 → 7 (-5)
59% less capital invested
Capital invested by funds: $1.31B → $541M (-$771M)
91% less call options, than puts
Call options by funds: $455K | Put options by funds: $5.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$16.2M |
| 2 |
Jennison Associates
New York
|
+$14.8M |
| 3 |
CC
Checkpoint Capital
San Francisco,
California
|
+$9.53M |
| 4 |
Morgan Stanley
New York
|
+$6.53M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$30.7M |
| 2 |
O
OrbiMed
New York
|
-$26.2M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$25.4M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$19.6M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$19.5M |
PHAT Hedge Fund Activity: Q4 2024 in Review
144 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2024, worth a combined $541M — down 59% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PHAT positions and 22 closed out — a net gain of 14 holders — while 60 added to existing stakes and 26 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $16.2M. The largest seller was Portolan Capital Management, exiting entirely with an estimated $30.7M sold.
- 144 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2024, up from 133 in Q3 2024.
- Funds reported $541M of Phathom Pharmaceuticals stock for Q4 2024, down 59% quarter-over-quarter.
- 36 funds opened new Phathom Pharmaceuticals positions in Q4 2024 and 22 closed out, a net change of +14 holders.
- The largest Phathom Pharmaceuticals buyer in Q4 2024 was Wasatch Advisors, an estimated $16.2M added.
- The largest Phathom Pharmaceuticals seller in Q4 2024 was Portolan Capital Management, an estimated $30.7M sold.
Based on aggregated 13F filings for Q4 2024.